NCT06376916RecruitingPhase 3
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 153 (estimated)
- First submitted
- 15 Apr 2024
- Start date
- 7 Oct 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Atrial fibrillation
- NCT number
- NCT06376916
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 153
- From 7 Oct 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously enrolled in this trial during a different patient encounter
Other illness
- End stage renal disease on hemodialysis or peritoneal dialysis
- Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
- Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response
- Acute myocardial infarction
- Allergy or sensitivity to any study drugs
Lab values
- Contraindications to magnesium sulfate (including myasthenia gravis)
Other
- Hemodynamically unstable patients (SBP \<90, MAP \<65)
- Impaired consciousness
- Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
- Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)
- Withdrew from study
Who the study is looking for
- Age \> 18 years or older
- Able to provide informed consent
- Primary diagnosis AFF RVR greater than or equal to 120 bpm
- Diltiazem as rate control agent
- English speaking
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Advocate Christ Medical Center Emergency Department (ACMC ED) Coordinator of this site? Confirm its status | Oak Lawn | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.